Liquidia Co. (NASDAQ:LQDA) General Counsel Sells $30,034.80 in Stock

Liquidia Co. (NASDAQ:LQDA) General Counsel Russell Schundler sold 2,060 shares of Liquidia stock in a transaction dated Friday, April 12th. The shares were sold at an average price of $14.58, for a total transaction of $30,034.80. Following the sale, the general counsel now owns 486,027 shares of the company’s stock, valued at approximately $7,086,273.66. The sale was disclosed in a document filed with the SEC, which is available through this link.

Russell Schundler also recently made the following trade(s):

• On Monday, March 18th, Russell Schundler sold 8,653 shares of Liquidia stock. The shares were sold at an average price of $15.82, for a total transaction of $136,890.46.

Liquidia Price Performance

NASDAQ LQDA opened at $13.29 on Friday. The company’s 50-day simple moving average is $14.74 and its two-hundred day simple moving average is $10.97. Liquidia Co. has a one year low of $5.71 and a one year high of $16.99.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings data on Wednesday, March 13th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.19). Liquidia had a negative return on equity of 132.16% and a negative net margin of 448.89%. The firm had revenue of $4.53 million during the quarter, compared to analysts’ expectations of $5.29 million. Analysts predict that Liquidia Co. will post -1.01 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have commented on LQDA shares. Needham & Company LLC reissued a “buy” rating and set a $28.00 target price on shares of Liquidia in a research report on Wednesday, April 10th. HC Wainwright raised their target price on shares of Liquidia from $16.00 to $32.00 and gave the company a “buy” rating in a research report on Thursday, March 14th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $21.00.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the company. Price T Rowe Associates Inc. MD grew its position in shares of Liquidia by 9.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 11,342 shares of the company’s stock worth $137,000 after buying an additional 989 shares during the last quarter. SkyView Investment Advisors LLC grew its position in shares of Liquidia by 1.4% in the 4th quarter. SkyView Investment Advisors LLC now owns 111,571 shares of the company’s stock worth $1,342,000 after buying an additional 1,571 shares during the last quarter. BNP Paribas Arbitrage SNC grew its position in shares of Liquidia by 20.5% in the 1st quarter. BNP Paribas Arbitrage SNC now owns 9,993 shares of the company’s stock worth $69,000 after buying an additional 1,702 shares during the last quarter. Chartwell Investment Partners LLC grew its position in shares of Liquidia by 6.0% in the 4th quarter. Chartwell Investment Partners LLC now owns 31,024 shares of the company’s stock worth $197,000 after buying an additional 1,769 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its position in Liquidia by 7.1% during the 4th quarter. JPMorgan Chase & Co. now owns 27,923 shares of the company’s stock worth $178,000 after purchasing an additional 1,845 shares during the last quarter. Hedge funds and other institutional investors own 64.54% of the company’s stock.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).